Home › Salivary Gland Cancer › Texas › Houston
Salivary Gland Cancer clinical trials in Houston, TX
5 studies for Salivary Gland Cancer are looking for participants at sites in and around Houston (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers
RecruitingPhase 2
- M D Anderson Cancer Center, Houston
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
RecruitingPhase 2
- MD Anderson Cancer Center, Houston
Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
RecruitingPhase 1
- Baylor St. Luke's Medical Center, Houston
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
RecruitingPhase 1/2
- The University of Texas MD Anderson Cancer Center (site 127), Houston
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
RecruitingPhase 1/2
- MD Anderson Cancer Center, Houston
About Salivary Gland Cancer
Salivary glands empty saliva into your mouth. Salivary gland cancer is a rare type of head and neck cancer. Learn about the associated symptoms.
More about Salivary Gland Cancer on MedlinePlus
Salivary Gland Cancer trials in other cities
- Nashville, TN5 studies
- Boston, MA5 studies
- New York City, NY4 studies
- Philadelphia, PA3 studies
- Dallas, TX3 studies
- Highlands Ranch, CO3 studies
Other studies in Houston
- Non-Small Cell Lung Cancer145 studies
- Breast Cancer126 studies
- Cancer (all types)121 studies
- Metastatic Cancer104 studies
- Colorectal Cancer102 studies
- Ovarian Cancer89 studies
- Acute Myeloid Leukemia85 studies
- Lung Cancer78 studies
- Prostate Cancer76 studies
- Endometrial Cancer68 studies
- Pancreatic Cancer61 studies
- Melanoma59 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.